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or to refine the decision formulation if uncertainty is high, potentially leading to 
improved decision-making.
PRM205
SySteMatic Review and cRitical aPPRaiSal of the StatiStical 
MethodS USed in PUbliShed StUdieS to indiRectly coMPaRe novel 
anticoagUlantS (noacS) with waRfaRin foR the PRevention of 
StRoke in PatientS with atRial fibRillation (af)
Daacke I.M.
Boehringer Ingelheim UK, Bracknell, UK
IntroductIon: The three main novel anticoagulants (NOACs) currently licensed 
in Europe, apixaban, dabigatran and rivaroxaban, have all been directly compared 
against warfarin in randomised controlled trials. However, none of the three drugs 
have been directly compared against each other. Thus, there has been an increase 
in the number of meta-analyses and indirect comparisons published comparing 
the relative efficacy and safety of these novel anticoagulants against each other 
via warfarin as a common comparator. objectIves: Systematically review all 
meta-analyses and indirect comparisons evaluating the NOACs against warfarin 
for the prevention of stroke in patients with AF and critically appraise the statistical 
methods used to do so. Methods: Systematic searches of EMBASE, MedLine, EBM 
Reviews, EconLIT as well as manual searches of ClincalTrials. gov, the Cochrane 
Library, CADTH, NICE, NHSEED and HTA were conducted. Data was abstracted from 
any citation applying statistical methods to compare the efficacy and safety of 
NOACs for the prevention of AF-related stroke. Information regarding the statistical 
approach; model assumptions; data presentation; interpretation of the evidence; 
and discussions of internal and external validity was used to quality rate each 
study. results: Bucher’s method of adjusted indirect comparison was most widely 
used. There were generally three main model assumptions required: the similarity, 
homogeneity and consistency assumptions, each being investigated with varying 
scrutiny in the studies reviewed. According to the quality assessment, the indirect 
comparison conducted by Wells and colleagues (2012) is of the highest relative qual-
ity. conclusIons: The limited number of RCTs available comparing the NOACs to 
standard therapy, creates considerable uncertainty surrounding the comparative 
efficacy and safety of these anticoagulants. In order to establish which individual 
NOAC is most likely to benefit a given patient population, indirect comparisons and 
meta-analyses are increasingly used. However, the quality of indirect comparison 
studies are variable and results should be interpreted with care.
PRM206
Methodological aSSeSSMent of Matching-adjUSted indiRect 
coMPaRiSonS: caSe StUdy aPPlication to attention deficit/
hyPeRactivity diSoRdeR (adhd)
Shafrin J.1, Sikirica V.2, Shrestha A.1, Henkhaus L.E.3, Erder M.H.2, Chandra A.4
1Precision Health Economics, Los Angeles, CA, USA, 2Shire Development, LLC, Wayne, PA, USA, 
3University of Southern California, Los Angeles, CA, USA, 4Harvard University, Cambridge, MA, 
USA
objectIves: Matching-adjusted indirect comparison (MAIC) is a novel comparative 
effectiveness approach to address biases that can appear in traditional indirect 
comparison (IC) methods when patient characteristics differ across trials. We exam-
ined three unanswered MAIC methodological questions and applied the proposed 
solutions to a comparison of ADHD treatments. Methods: Using individual patient 
data from two randomized controlled trials (RCTs) comparing guanfacine (GXR) 
vs placebo and published summary statistics from four RCTs comparing atomox-
etine (ATX) vs placebo, MAIC was used to reweight the GXR data so that observable 
GXR patient characteristics matched those of ATX patients. Change in ADHD-RS-IV 
scores was the primary endpoint. Comparative efficacy results were evaluated for 
their sensitivity to changes in the following three MAIC specifications: variable 
selection using regression-based methods, statistical moments matched (i.e., mean 
vs mean and variance), and matching on placebo-arm outcomes. results: Both 
treatments decreased ADHD-RS-IV scores relative to placebo (-17.9 GXR vs -10.7 
placebo; -14.6 ATX vs -5.8 placebo). In the baseline MAIC specification adjusting for 
patient baseline characteristics and placebo arm outcomes, GXR produced larger 
decreases in ADHD-RS-IV scores than ATX (Δ : -3.9, p< 0.004). The results were insen-
sitive to adding variables to the matching algorithm (Δ : -3.8, p< 0.023), or match-
ing only covariate means rather than both means and variances (Δ : -3.6, p< 0.006). 
Applying MAIC without matching placebo arm outcomes indicated a slightly greater 
decrease in ADHD-RS-IV scores for ATX, but there was no statistically significant 
difference between GXR and ATX (Δ : 0.6, p< 0.649). conclusIons: In this study, 
MAIC results were insensitive to variable selection via regression and the statistical 
moments matched, but matching the placebo arms altered the results. Matching 
placebo arm outcomes is valid when unobserved trial-specific factors have a dif-
ferential impact on a trial’s treatment and control arm outcomes; this was likely 
the case in this GXR-ATX study.
PRM207
PRoPoSed checkliSt foR non-StatiSticianS to aSSeSS the QUality of a 
netwoRk Meta-analySiS in the context of a nice SUbMiSSion
Pacou M.1, Gauthier A.2, Taieb V.2, Bec M.2, Belhadi D.2, Guillemot J.2
1Amaris, Paris, France, 2Amaris, London, UK
objectIves: To develop a checklist to assess the quality of a network meta-analysis 
(NMA) in the context of a submission to NICE. This checklist is intended to be com-
prehensible and easy-to-use by non-statisticians to assess whether an NMA is suit-
able for a submission to NICE and/or to populate cost-effectiveness models within 
the context of the NICE requirements. Methods: An ad-hoc search of the literature 
was conducted to identify existing checklists. Items from these checklists were 
extracted and critically reviewed. Recommendations from NICE as well as existing 
NICE submissions and corresponding comments from the evidence review groups 
(ERG) were used to develop the checklist. Our checklist was validated by health 
economists and pharmacists not trained in NMA on the basis of a NICE submission 
to promote awareness on the medications, balanced diet and physical activity to 
improve the quality of life of an individual.
PRM202
SiMUlating individUal Patient level data to addReSS tReatMent 
Switching when only SUMMaRy data aRe available
Boucher R., Abrams K., Lambert P.C.
University of Leicester, Leicester, UK
objectIves: Treatment switching commonly occurs in the pivotal HTA evidence 
for advanced or metastatic cancer treatments submitted to reimbursement agen-
cies. Simple approaches, such as Intention-to-treat (ITT) analysis, have typically 
been used to analyse data with treatment switching, despite simulation studies 
showing these to drastically underestimate the underlying treatment effect. With 
more manufacturers conducting indirect comparisons (ICs) to compare treatments, 
summary data are being used more in analysis. The method outlined addresses 
treatment switching when only summary data are available to ensure appropri-
ate estimates for the treatment effect are achieved when the data is then used 
in an IC. Methods: Using digitised survival curves, multiple datasets that are 
representative of the original individual patient data (IPD) are simulated. Treatment 
switching information is estimated from reported information on progression-free 
survival, and then established methods which adjust appropriately for treatment 
switching used to analyse the simulated data. This approach is applied to an exam-
ple from a technology appraisal (TA) submitted to National Institute for Health and 
Care Excellence (NICE), and the ITT hazard ratio and median survival obtained and 
compared with those reported, before analysis using a Rank Preserving Structural 
Failure Time Model (RPSFTM). results: Averaging over 2000 datasets, the replicated 
summary statistics were similar to those reported. Both median survival times were 
within 1 month of those stated in the TA and the hazard ratio less than 0.05 differ-
ent. Subsequent analysis using an RPSFTM shows the new treatment to be more 
effective, and inappropriately adjusting for crossover to have underestimated the 
treatment effect. conclusIons: Adjusting summary data is important as other-
wise, subsequent analysis conducted will give inappropriate results. The simulated 
data approach well represents the original IPD, giving on average similar results to 
those reported. Hence, the further analysis to address treatment switching issues 
gives more appropriate treatment effect estimates.
PRM203
Modeling the effect of coMbining alogliPtin with dUal theRaPy in 
tyPe 2 diabeteS
Johnson K.I.1, Palin H.J.1, Sibbring G.C.1, Selby R.2
1Complete Clarity, Macclesfield, UK, 2Takeda UK, High Wycombe, UK
objectIves: To estimate the impact of combining the dipeptidyl peptidase-4 (DPP-
4) inhibitor, alogliptin, with metformin and sulfonylurea (alogliptin triple therapy) 
to achieve glycemic control in patients with type 2 diabetes. Methods: Since no 
clinical trial of alogliptin triple therapy has been conducted, the effect of adding 
alogliptin to dual therapy (metformin+sulfonylurea) was modeled using novel addi-
tive effect methodology, utilizing data from a previous mixed treatment comparison 
(MTC). The following assumptions were made: the efficacy of triple therapy can be 
estimated as a function of its constituent parts, and the efficacies of the constituent 
parts are equivalent. Pooled data for the absolute change from baseline in glyco-
sylated hemoglobin (HbA1c) from trials of sitagliptin, linagliptin, and vildagliptin 
triple therapy, and for their constituent parts, informed the model. A weighting fac-
tor, β coefficient, derived from DPP-4 mono, dual, and triple therapy trials, was used 
to estimate the effect size for triple therapy using the sum of the constituent parts. 
The estimated mean β value was validated against the observed effect size of alog
liptin+pioglitazone+metformin, using the pooled effect from the MTC. results: 
An estimated mean β coefficient value of 0.83 represented the DPP-4 inhibitor class. 
Validation of the approach resulted in a similar β coefficient for pioglitazone triple 
therapy (0.82). Absolute change in HbA1c from baseline for alogliptin triple therapy 
was estimated as -0.77% (95% CI -1.16, -0.39). Similar values were observed in the 
MTC for sitagliptin -0.94% (95% CI -7.34,5. 40), linagliptin -0.65 (95% CI -6.87,5. 60), 
and vildagliptin -0.80% (95% CI -7.00,5. 43). conclusIons: The wide confidence 
interval is consistent with expectations in the literature and is a limitation of the 
method employed, in that it requires the variance of the individual studies to be 
summated. Nevertheless, the method demonstrates the value of modeling when 
clinical trial evidence is not available.
PRM204
UnceRtainty and PRobabiliStic MethodS in MUlti-cRiteRia deciSion 
analySiS
O Meachair S., Walsh C.
Trinity College Dublin, Dublin, Ireland
objectIves: Multi-Criteria Decision Analysis (MCDA) is a collection of techniques 
for choosing optimal decisions when two or more criteria need to be taken into 
account in the decision process. Most MCDA techniques require the specification 
of a number of parameters; criteria weights, utility functions or indifference thresh-
olds. We wish to account for the uncertainty in these parameters which may arise 
due to the fuzzy nature of the Decision Maker’s preferences, conflicting opinions 
between a group of decision makers or population group, or the abstract nature of 
the parameters. Methods: We implement some MCDA models from a Bayesian 
perspective where parameters come from posterior probability distributions repre-
senting the combination of available knowledge on the parameters. Such knowledge 
can come from empirical data, expert elicitation, survey data, decision-making com-
mittees, or some combination of these. results: Depending on the method used, 
the end result is either a benefit function which quantifies the uncertainty in the 
benefit score for each action, or a rankogram which depicts the uncertainty in the 
ranking of actions. conclusIons: Knowledge about this uncertainty allows deci-
sion makers to make more informed decisions. A decision action may be clear when 
uncertainty is sufficiently low, or it may be necessary to request more information 
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to ≥ 3 groups which initiate double-blind active therapy at different times from 
baseline, preceded by 0,1, 2 or more intervals of placebo. Analytical and simulation-
based investigations were conducted to compare the statistical power, required 
assumptions, practical considerations and economic features of the Blind Start to 
conventional single-arm and randomized designs. results: Given the same num-
ber of patients, the randomized Blind Start provides equivalent statistical power for 
detecting changes pre- vs. post-treatment compared to a conventional single-arm 
design. However, by concealing treatment initiation times, the Blind Start enables 
more objective assessments of outcomes that are effort-based, patient-reported 
or subjectively assessed by investigators. In addition, compared to a conventional 
2-arm randomized trial, analysis of parallel treatment and placebo groups embed-
ded within a Blind Start design provides greater power to detect treatment effects 
over any fixed time interval. For example, with N= 16 and a treatment effect equal 
to 1 standard deviation of the outcome measure, a 4-arm Blind Start design provides 
85% power in a pre-post analysis and 79% power in an analysis of embedded paral-
lel groups. In contrast, a conventional 2-arm randomized trial provides 52% power 
in this scenario. Benefits of the Blind Start design come at the expense of 1) more 
patient-time in the trial and 2) lack of stringent control over patient status upon 
active treatment initiation. conclusIons: The randomized Blind Start design can 
improve precision for treatment effect estimation vs. parallel-group designs and 
reduce risk of bias vs. single-arm designs. Endpoint choice and statistical analysis 
strategies for the Blind Start design can maximize the assessment of treatment 
effects on multiple outcomes.
ReSeaRch on MethodS – Study design
PRM212
the QUality of SeaRch Methodology and SeaRch RePoRting in 
PUbliShed SySteMatic ReviewS of econoMic evalUationS:  
SeaRch SoURceS
Wood H., Arber M., Glanville J.
York Health Economics Consortium, York, UK
objectIves: The economic evaluation of health care interventions is now an 
accepted element of health care decision-making and priority-setting. As the num-
ber of published economic evaluations has grown, so has the number of systematic 
reviews of economic evaluations. However, the quality of search methodology used in 
recent reviews has not been widely investigated. This study sought to identify which 
search resources are being used to identify studies in recent, published systematic 
reviews of economic evaluations, and to investigate whether choice of resources 
reflects current recommendations for the conduct of such reviews. Methods: 
A search to identify systematic reviews of economic evaluations published since 
January 2013 was undertaken in MEDLINE. Two reviewers extracted the following 
information from reviews which met the inclusion criteria: general medical litera-
ture databases searched, specialist economic databases searched, health technology 
assessment sources searched, supplementary search techniques used. Results were 
compared against the search resources recommended by NICE when searching for 
economic evidence for single technology appraisals, and the summary of current 
best evidence provided in Sure Info (http://vortal.htai.org/?q= node/336). results: 
Sixty-five systematic reviews met the inclusion criteria; 23 of these could not be 
accessed in full text, data was extracted from 42 reviews. Five reviews (12%) met 
or exceeded the search resources recommended by NICE (MEDLINE, Embase, NHS 
EED, EconLit). Nine reviews (21%) searched at least four of the six types of resource 
recommended by Sure Info (specialist economic databases, general databases, HTA 
databases, webpages of HTA agencies, grey literature, collections of utility studies). 
None of the reviews searched all six. Although all reviews explicitly described the 
resources searched, reporting frequently contained errors or lack of clarity in the 
names of databases and interfaces. conclusIons: The information resources used 
to identify evidence for the majority of recently published systematic reviews of 
economic evaluations do not conform to current recommendations.
PRM214
identifying PSoRiaSiS and PSoRiatic aRthRitiS PatientS in 
RetRoSPective databaSeS when diagnoSiS code iS not available: 
a validation StUdy coMPaRing Medication/PReScRibeR viSit baSed 
algoRithMS to diagnoSiS codeS
Dobson-Belaire W.1, Borrelli R.1, Goodfield J.1, Liu F.F.2, Khan Z.M.3
1IMS Brogan, Mississauga, ON, Canada, 2Celgene Inc., Mississauga, ON, Canada, 3Celgene 
Corporation, Summit, NJ, USA
objectIves: Retrospective database studies rely on the ability to accurately iden-
tify patient cohorts of interest within health care databases. Diagnosis code-based 
algorithms are the primary method of identifying patient cohorts; however, many 
databases lack reliable diagnosis code information. Our aim was to develop precise 
algorithms based on medication claims/prescriber visit (MC/PV) to identify psoriasis 
(PsO) patients or psoriatic patients with arthritic conditions (PsO-AC), a proxy for 
psoriatic arthritis, in databases lacking diagnosis codes. Methods: Algorithms 
were developed using medications with narrow indication profiles in combina-
tion with prescriber specialty to define PsO and PsO-AC. For the study period of 
July 1, 2009 to June 30, 2013, algorithms were validated using the PharMetrics Plus™ 
(PharMetrics) database, which contains both adjudicated medication claims and 
diagnosis codes. Positive predictive value (PPV), negative predictive value (NPV), sen-
sitivity and specificity of algorithms developed for PsO and PsO-AC were assessed 
using diagnosis code as the reference standard. results: In the PharMetrics data-
base, 183,328 patients were identified by diagnosis code or medication claim for vali-
dation. The highest PPVs for PsO (85%) and PsO-AC (65%) occurred when a predictive 
algorithm of ≥ 2 MC/PVs was compared to the reference standard of ≥ 1 diagnosis 
code. The majority of PsO-AC false positives had a diagnosis of PsO and pain or joint 
symptoms. NPV and specificity were also high (99 – 100%), while sensitivity was low 
(≤ 30%). Reducing the number of MC/PVs or increasing diagnosis claims decreased 
in type 2 diabetes mellitus. Comprehension of the checklist was assessed based 
on qualitative interviews of each analyst. A measure of the inter-analysts agree-
ment was estimated to ensure the reliability of the checklist. results: Checklists 
identified from the literature included the checklist developed by the NICE Decision 
Support Unit and the one developed by the ISPOR task force. These two checklists 
were developed for analysts who conduct NMAs as well as analysts who critically 
review NMAs. However, they seem to lack clarity for non-statisticians. We developed 
a new checklist, which included the following items: definition of the study question 
(list of comparators, study population), methods (study selection, data extraction, 
statistical model, selection of fixed versus random effects model, assumptions for 
the base case, heterogeneity and inconsistency assessment and sensitivity analy-
ses), reporting of results (network and source data, median or mean and 95% cred-
ibility interval) and interpretation of results. conclusIons: Our checklist can be 
used by analysts not trained in statistics to prepare or review NMAs to be submitted 
to NICE and/or to populate cost-effectiveness models.
PRM208
Methodology foR Selecting exPeRt gRoUPS foR the PURPoSe of 
deciSion-Making taSkS
Ivlev I.1, Bartak M.2, Kneppo P.1
1Czech Technical University in Prague, Kladno, Czech Republic, 2Jan Evangelista Purkyne 
University, Usti nad Labem, Czech Republic
objectIves: This work aims to develop a methodology for determining the qualita-
tive composition of an expert group for the purpose of participation in decision-
making in health care technology. Its goal is also to evaluate the methodology 
based on an example of the selection of large medical equipment. Methods: The 
complex weighting factor is a comprehensive evaluation of an expert. It is based 
on the expert’s overall work experience, experience in solving tasks, level of educa-
tion and scientific record, interest in solving the particular task, current position, 
and awareness of how to solve the task. Also taken into account are the relevance 
of the expert’s knowledge and the overall self-evaluation concerning his or her 
total competence in solving the task. For the purpose of validating the method-
ology, 96 potential experts were interviewed. These subjects included managers 
from relevant departments in hospitals and hospital staff members who were from 
72 health facilities in the Czech Republic. results: Unlike the other models, the 
calculation model that was selected is able to eliminate errors in estimating the 
proportionality of extreme values and to reduce the impact of uncertainty in the 
experts’ overall self-evaluations concerning their total competence to the combined 
ratio. Based on this model, a methodology for selecting experts was developed. A 
statistically significant correlation was found between the complex weighting factor 
and the following characteristics: the expert’s experience in dealing with similar 
tasks (r= 0.512, p< 0.001), the expert’s theoretical background (awareness) and the 
relevance of the expert’s knowledge (r= 0.44, p< 0.001), the expert´s current position 
(r= 0.319, p= 0.002), and the level of his or her education and scientific record (r= 0.28, 
p= 0.007). conclusIons: This methodology will be especially useful in scientific 
and technological forecasting, medical and managerial decision-making, quality 
assessment, and operational research.
PRM210
Modelling longitUdinal tRajectoRieS of Patient-RePoRted oUtcoMeS 
to evalUate tReatMent effect
Jen M.H.
Eli Lilly and Company, Surrey, UK
objectIves: To evaluate treatment effect on longitudinal patient-reported out-
comes using appropriate analytical strategy. Methods: This was an ad-hoc analy-
sis of longitudinal patient-reported outcomes using a two stages simulated data 
in which the true model is known, to explore and to evaluate the capability of the 
group-based trajectory method to identify the distinctive features of a highly irregu-
lar but still continuous population distribution of trajectories. Firstly, we created 
six different types of underlying trajectory in which the true model is known and 
added in level-one between occasion random noises. Then we added a level-two, 
between- patients variation (of the random intercept form) with differing variabil-
ity to each of the six distinctive trends. This simulation allows us to examine how 
the software implementation identifies different group trajectories as well as their 
level-one and -two variances. It was recognized that a priori assignment of distinct 
longitudinal trajectories may not be appropriate and that no ability to calibrate 
the precision of individual classifications exists if ex-ante rules are used. Thus, 
latent group-based trajectory model, a method to map the developmental course of 
symptoms and assess heterogeneity in response to clinical interventions, was used 
to identify patient groups with varied response. results: The fitted trajectories 
closely approximate the true shapes and there is also a close correspondence for the 
percentage of places attributed to each group. Even the size of the level 1 random 
term is correctly estimated. The semi-parametric group-based trajectory method 
has demonstrated unequivocally its capability to capture the unobserved subgroups 
in the presence of considerable level-1 random variation. conclusIons: Patients 
in many disease areas experience changes in QoL in different ways. Identification 
of those groups is essential for appropriate evaluation of therapy treatment effects 
and identification of factors contributing to those groupings.
PRM211
the RandoMized blind StaRt tRial: evalUation of a new StUdy 
deSign foR aSSeSSing clinical oUtcoMeS in RaRe and heteRogeneoUS 
Patient PoPUlationS
Signorovitch J.1, Ayyagari R.2, Kakkis E.3
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group Inc., Boston, MA, USA, 3Ultragenyx 
Pharmaceutical Inc., Novato, CA, USA
objectIves: Clinical development of therapies for rare diseases can benefit from 
improvements to conventional trial designs. This study evaluated a new trial design, 
the randomized Blind Start. Methods: The Blind Start design randomizes patients 
